Bridgeway Capital Management, LLC Solid Biosciences Inc. Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.43 - $1.24 $43,000 - $124,000	-100,000 Reduced 25.3%	295,300 $182,000
Q1 2022 May 16, 2022	BUY	$0.74 - $1.79 $148,000 - $358,000	200,000 Added 102.41%	395,300 $474,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $268,372 - $390,648	158,800 Added 435.07%	195,300 $342,000
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $218,722 - $346,463	-91,900 Reduced 71.57%	36,500 $87,000
Q2 2021 Aug 16, 2021	SELL	$3.49 - $5.51 $163,946 - $258,837	-46,976 Reduced 26.79%	128,400 $470,000
Q4 2020 Feb 16, 2021	SELL	$3.08 - $7.79 $141,680 - $358,340	-46,000 Reduced 20.78%	175,376 $1.33 Million
Q3 2020 Nov 16, 2020	BUY	$2.02 - $3.08 $161,600 - $246,400	80,000 Added 56.59%	221,376 $449,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $3.42 $175,140 - $285,228	83,400 Added 143.85%	141,376 $414,000
Q1 2020 May 15, 2020	BUY	$2.31 - $4.43 $27,664 - $53,053	11,976 Added 26.03%	57,976 $139,000
Q3 2019 Nov 14, 2019	BUY	$4.33 - $11.64 $199,180 - $535,440	46,000 New	46,000 $476,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $42.1M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.